Fehnel S. Establishing optimal requirements for content validity: a work in progress. Value Health. 2009 Nov 1;12(8):1074.
Wolowacz S, Samuel M, Brennan VK, Jasso-Mosqueda J, van Gelder I. The cost of illness of atrial fibrillation: a systematic review. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A325.
Wilburn J, McKenna SP, Twiss J. Further developments of the rheumatoid arthritis quality of life scale (RAQoL). Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, Spain. [abstract] Value Health. 2009 Oct; 12(7):A447-8. doi: 10.1016/S1098-3015(10)75215-3
Twiss J, Doward LC, McKenna SP, Eckert B. Interpreting scores on the multiple sclerosis-specific PRIMUS and U-FIS outcome measures. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A373. doi: 10.1016/S1098-3015(10)74836-1
Twiss J, McKenna SP, Preston E, Meads DM. Can we rely on scores from the dermatology life quality index? Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A460. doi: 10.1016/S1098-3015(10)75277-3
Kauf T, Davis KL, Earnshaw S, Davis EA, Watson ME. Spillover adherence effects of fixed-dose combination HIV therapy. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A430.
Mauskopf J, Graham JB, Bae J, Gaich C. Impact of including prasugrel on the formulary for patients who undergo percutaneous coronary intervention for acute coronary syndrome. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A322.
Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.
Zimovetz E, Wolowacz S. Reviewer's checklist for assessing the quality of decision models. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A395.
Papanicolaou S, Kontodimas S, Syriopoulou E, Tsolia M, Theodoridou M, Kremastinou J, Tzanakaki G, Strutton D, Hwang S, Earnshaw SR. Clinical and economic benefits of national immunization with the 13-valent compared to 7- and 10-valent pneumococcal conjugate vaccines in Greece. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A423-4.
Farkouh R, Wilson M, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with other first-line treatment options for early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A369.
Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.
de Cambra S, Mladsi D, Neale S, Faulkner EC. Reimbursement of active immunotherapeutics: an analysis based on a study of current reimbursement approaches. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A288. doi: 10.1111/j.1524-4733.2009.00592_1.x
de Cambra S, Mladsi D, Neale S. International payer research: comparing and contrasting payer roles and research methods in Canada, Spain, and the UK. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A245. doi: 10.1111/j.1524-4733.2009.00592_1.x
Ismaila A, Pereira J, Robson R, Talbird SE, Standaert B, Rawson N. Budget-impact analysis of adding the new 10-valent pneumococcal conjugate vaccination (PHiD-CV) to routine infant vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A418.
Whillans F, Kwan H, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent and 10-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A425.
Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication nonadherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A355.
Gonzalez-Rojas N, Vieta A, Monreal M, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism following total hip or knee replacement in Spain. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 24, 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A440.
Jeuland M, Cook J, Poulos C, Clemens J, Whittington D. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health. 2009 Sep 1;12(6):899-908.
Arbuckle R, Clark M, Harness J, Bonner N, Scott J, Draelos Z, Rizer R, Yeh Y, Copley-Merriman K. Item reduction and psychometric validation of the oily skin self assessment scale (OSSAS) and the oily skin impact scale (OSIS). Value Health. 2009 Jul 1;12(5):828-37.
Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.
Watson V, Ryan M, Watson E. Valuing experience factors in the provision of Chlamydia screening: an application to women attending the family planning clinic. Value Health. 2009 Jun;12(4):621-3. doi: 10.1111/j.1524-4733.2008.00451.x
Lee LJ, Nelson LM, McLeod LD, Hill CD, Sweeney CT. Effects of insulin therapy on the Diabetes Symptom Checklist-Revised (DSC-R): data from a large insulin clinical trial. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 12(3):A105.
Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.
Soorapanth S, Brogan AJ, Mrus J, Smets E. Comparative cost-efficacy analysis of darunavir/r for first-line treatment of HIV infection in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 2009. [abstract] Value Health. 12(3):A112.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty with moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Mauskopf J, Schmitt C, Boye KS, McCollam PL, Juniper MD, Birt JA. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(2):A148.
Mordin MM, Clark M, Siersma CA, Copley-Merriman K, Gnanasakthy A. Impact of the FDA draft guidance on patient reported outcomes (PRO) label claims for approved drug products in the US: has it made a difference? Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 19, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A29.
Farkouh RA, Wilson MR, Tarrants M, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline versus ropinirole extended release in delaying levodopa in the treatment of early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(3):A192.
Mateus C, Wolowacz S, Pereira JA. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A148.
Khan SB, Zagar AJ, Hayes CP, DiBenedetti DB, Zhou X, Price M, Van Brunt DL. Assessment of type 2 Diabetes mellitus patients with and without symptoms of ADHD: patient characteristics and resource utilization data from an internet-based survey. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May 1; 12(3):A181-2.
Doward LC, McKenna SP, Meads DM, Kahler K, Frech F. The development of the Herpes Symptom Checklist (HSC) and the Herpes Outbreak Impact Questionnaire (HOIQ). Value Health. 2009 Jan 1;12(1):139-45.
Brogan AJ, Soorapanth S, Donatz V, Hill A, Smets E. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. Paris, France. [abstract] Value Health. 2009; 12(7):A426.